CHM 6.67% 1.6¢ chimeric therapeutics limited

There seems to be quite a remarkable mismatch in valuation...

  1. 1,516 Posts.
    lightbulb Created with Sketch. 505
    There seems to be quite a remarkable mismatch in valuation between Arovella Therapeutics and Chimeric, with ALA still in the pre-clinical phase compared to CHM with multiple platforms and clinical trials. Is their iNKT cell platform likely to be superior to CHMs core-NK platform in the long-run? If not, any comments on the valuation mismatch?
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
(20min delay)
Last
1.6¢
Change
0.001(6.67%)
Mkt cap ! $14.29M
Open High Low Value Volume
1.6¢ 1.7¢ 1.6¢ $18.31K 1.150M

Buyers (Bids)

No. Vol. Price($)
3 287280 1.6¢
 

Sellers (Offers)

Price($) Vol. No.
1.7¢ 617827 2
View Market Depth
Last trade - 16.10pm 11/09/2024 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.